Review



alimta  (Eli Lilly)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Eli Lilly alimta
    Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/alimta/us12655159-436-11-12
    Average 86 stars, based on 1 article reviews
    alimta - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    MTT Assay:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Incubation:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Control:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Inhibition:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Concentration Assay:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Fluorescence:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Membrane:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.

    Marker:

    Article Title: Analysis of patentability factors and its impact on claim protection and prosecution timelines for pharmaceutical patents
    Article Snippet: The pharmaceutical industry faces unique challenges in patent prosecution due to the broad scope of innovations that patents cover.. Navigating the patent prosecution process is arduous due to various factors, including its inherent complexity and the potential for patentability rejections.. The study developed a new dataset containing the Orange Book listed patents based on USFDA calendar year 2020 approvals.

    Article Title: Antibody-drug conjugates comprising anti-B7-H3 antibodies
    Article Snippet: Representative examples include, but are not limited to, methotrexate, 4-amino-folic acid (also known as aminopterin and 4-aminopteroic acid), lometrexol (LMTX), pemetrexed (Alimpta, Eli Lilly and Company), and trimetrexate (Neutrexin, Ben Venue Laboratories, Inc.) Purine Antagonists The linkers of the disclosure may be used to conjugate an antibody to at least one purine antagonist.

    Article Title: MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Article Snippet: In combination with pembrolizumab, cisplatin, carboplatin and pemetrexed , NSCLC , Eli Lilly and Company , Phase III , NCT06119581.

    Article Title: The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment
    Article Snippet: Pemetrexed was purchased from Eli Lilly Co., diisopropylammonium dichloroacetate (DADA) was purchased from Sanglid Biotechnology Co. (stored at 4°C, protected from light and dry, ready for use), the anti-γ-H2AX antibody was purchased from Abcam (Shanghai) Trading Co., the anti-mouse CD3, anti-mouse CD4, and anti-mouse CD8 antibodies were purchased from BD (Becton, Dickinson and Company, BD) Biotechnology, and the anti-PD-1 antibody was purchased from Suzhou Junmeng.



    Similar Products

    pemetrexed  (MedChemExpress)
    94
    MedChemExpress pemetrexed
    Pemetrexed, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/Pemetrexed/10__1016_slash_j__ijpx__2026__100558-58-0-4
    Average 94 stars, based on 1 article reviews
    pemetrexed - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    tyms inhibitor pemetrexed  (Selleck Chemicals)
    94
    Selleck Chemicals tyms inhibitor pemetrexed
    (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM <t>TYMS</t> inhibitor <t>Pemetrexed</t> ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.
    Tyms Inhibitor Pemetrexed, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/Pemetrexed/pmc13684273-28-35-44
    Average 94 stars, based on 1 article reviews
    tyms inhibitor pemetrexed - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    alimta  (Eli Lilly)
    86
    Eli Lilly alimta
    (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM <t>TYMS</t> inhibitor <t>Pemetrexed</t> ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.
    Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/alimta/us12655159-436-11-12
    Average 86 stars, based on 1 article reviews
    alimta - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    mta  (Dentsply Sirona)
    86
    Dentsply Sirona mta
    (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM <t>TYMS</t> inhibitor <t>Pemetrexed</t> ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.
    Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/mta/pmc13266017-66-38-41
    Average 86 stars, based on 1 article reviews
    mta - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    proroot mta  (Dentsply Sirona)
    86
    Dentsply Sirona proroot mta
    (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM <t>TYMS</t> inhibitor <t>Pemetrexed</t> ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.
    Proroot Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/mta+proroot/pm42159272-165-4-6
    Average 86 stars, based on 1 article reviews
    proroot mta - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    pemetrexed  (Eli Lilly)
    86
    Eli Lilly pemetrexed
    Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal <t>pemetrexed</t> (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)
    Pemetrexed, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/alimta/pmc13192031-183-0-2
    Average 86 stars, based on 1 article reviews
    pemetrexed - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM TYMS inhibitor Pemetrexed ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.

    Journal: NAR Cancer

    Article Title: EXO1 inhibition selectively kills replication repair-deficient cancer cells

    doi: 10.1093/narcan/zcag029

    Figure Lengend Snippet: (A ) Representative images for micronuclei induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Yellow arrows point to each micronucleus. Scale bar: 20 μm. ( B ) Quantification of cells with micronuclei for eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥399 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate, with P -values denoted above columns. Mean with standard deviation is shown for each sample based on mean of the biological replicates. ( C ) Representative images for γH2AX signal induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( D ) Quantification of mean intensity of γH2AX in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( E ) Representative images for RPA32-pS33 foci induced by 24-h ART5537 treatment in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells. Nuclei borders are denoted with dotted lines. Scale bar: 20 μm. ( F ) Quantification of RPA-pS33 foci in eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells in untreated condition or after 24-h treatment with either 2.5 or 5 μM ART5537 ( n = 3, quantification based on ≥397 nuclei per condition). Ordinary two-way ANOVA was performed on means from each biological replicate (red line denotes overall mean), with P -values denoted above columns. ( G ) Immunoblotting of cell extracts from eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells following 24-h treatment with 5 μM ART5537. Samples were probed for phosphorylated levels of KAP1 and CHK2 with controls, and for beta-actin as loading control. ( H ) Quantification of clonogenic assay of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cell lines with 1 μM TYMS inhibitor Pemetrexed ( n = 3). ( I ) Survival of eHAP iCas9 wild type, FANCG KO, and ZRSR2 KO cells treated with ART5537 without or with TYMS inhibitor Pemetrexed ( n = 3); ordinary two-way ANOVA with Tukey’s test.

    Article Snippet: Compounds developed for EXO1 inhibition [compound 20, compound 29 (ART5537), and compound 30] [ ] were a generous gift from Artios Ltd, while ATM inhibitor (KU-55933), PARP inhibitor olaparib (AZD2281), PARP inhibitor veliparib (ABT-888), and TYMS inhibitor Pemetrexed ( LY231514 ) were purchased from Selleckchem.

    Techniques: Standard Deviation, Western Blot, Control, Clonogenic Assay

    Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

    Journal: BMC Cancer

    Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

    doi: 10.1186/s12885-026-15915-5

    Figure Lengend Snippet: Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

    Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

    Techniques: Biomarker Discovery

    The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

    Journal: BMC Cancer

    Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

    doi: 10.1186/s12885-026-15915-5

    Figure Lengend Snippet: The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

    Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

    Techniques: Biomarker Discovery